Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug-March 2024-www.financetom.com

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

Jun 24, 2025 4:25 AM

June 24 (Reuters) - Royalty Pharma ( RPRX ) said on

Tuesday will pay up to $2 billion to Revolution Medicines ( RVMD )

to support the companies' plans for global development

and commercialization of the experimental cancer drug

daraxonrasib.

Previous page： Sula Vineyards expects bumper harvest in early 2024 Next page： Cult US sneaker brand Foot Locker inks exclusive licensing deal with Metro Brands & Nykaa

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Sula Vineyards expects bumper harvest in early 2024

Nov 29, 2023

The unseasonal rainfall in Mumbai and other parts of the state prompted concerns about potential disruptions in the agricultural supply chain.

Cult US sneaker brand Foot Locker inks exclusive licensing deal with Metro Brands & Nykaa

Nov 29, 2023

The volume of the sneaker segment in India is projected to reach 66 million pairs by 2028. Shares of Metro Brands Ltd ended at ₹1,326.85, up by ₹27.10, or 2.09%, and shares of FSN E-Commerce Ventures Ltd ended at ₹172.10, up by ₹2.80, or 1.65%, on the BSE.

UltraTech Cement acquires Burnpur Cement's grinding assets in Jharkhand for ₹170 crore

Nov 29, 2023

This acquisition not only substantially hikes UltraTech Cement's capacity but also serves as a strategic entry into the promising market of Jharkhand. Shares of UltraTech Cement Ltd ended at ₹8,721.80, down by ₹6.20, or 0.071%, on the BSE.

Axis Mutual Fund eyes ₹3 lakh crore AUM by March, expects ₹2,500 crore from new fund

Nov 29, 2023

The fund house opened the year with an AUM (assets under management) of over ₹2.25 lakh crore. The open-ended equity scheme represents the manufacturing theme and opens for subscription on December 1 and closes on December 15.